



**COMMUNITY MEDICAL CENTER  
HEALTHCARE SYSTEM**

1800 Mulberry Street  
Scranton, Pennsylvania 18510  
570 969-8000

RECEIVED  
REGION 1

2006 JUN 12 PM 1:29

Br. 1

03003142

License No. 37-11507-01

June 5, 2006

United States Nuclear Regulatory Commission  
Region 1  
Medical Licensing  
475 Allendale Road  
King of Prussia PA 19406

Gentlemen:

Please amend our license authorizing Michael A Burke, M.D. for 35,400 manual brachytherapy using I125 seeds for prostate cancer therapy.

For questions regarding this request please call John C. Ramsey at 908-788-9440.

Thank you.

Sincerely yours,

C. Richard Hartman, M.D.  
Chief Executive Officer

Attachments

Cc: Nuclear Medicine

138980  
NMSS/RGNI MATERIALS-002

**NEW YORK STATE DEPARTMENT OF HEALTH  
RADIOACTIVE MATERIALS LICENSE**

License Number 559

Amendment Number 59

DH Number 03-669

Vassar Brothers Hospital  
1 Reade Place  
Poughkeepsie, New York 12601

Attention: Kenneth Chu, Ph.D.  
Radiation Safety Officer

Dear Licensee:

In accordance with the request dated December 11, 2003, signed by Susan Davis, RN, and Kenneth Chu, Ph.D., New York State Department of Health Radioactive Materials License No. 559 is amended as follows:

Change Condition No. 10 to Read:

10. A. Radioactive material listed in Item 6 shall be used by, or under the tutelage of the following individuals, with the specified limitations:

Michael A. Burke, M.D.	Subitems C, D, G and H
Joel Cantor, M.D.	Subitems A, B, C, F and I
Edward M. Farhangi, M.D.	Subitems C, D, and H
Henry J. Fischer, M.D.	Subitems A through F, and I
Victor D. Gaines, M.D.	Subitems A, B, C, F and I
William Z. Goldstein, M.D.	Subitems A, B, P-32 and Sr-89 of Subitem C, F, and I
Jack I. Hentel, M.D.	Subitems A, B, C, F and I
Susan A. Higgins, M.D.	Subitems C, D, G and H
Malcolm G. Idelson, M.D.	P-32 of Subitem C only
Russell Karp, M.D.	Subitems A, B, E, F and

**NEW YORK STATE DEPARTMENT OF HEALTH  
RADIOACTIVE MATERIALS LICENSE**

**CONDITIONS**

License No. 559

Amendment No. 59

## 10. A. (Continued)

Michael K. Kauff, M.D.

Subitems A, B, C, F and I

Taik H. Kim, M.D.

Sr-89 of Subitem C, Subitems D, G,  
and H

Thomas Mazzilli, M.D.

Subitems D, G and H

Dimitrios Papadopoulos, M.D.

Sr-89 of Subitem C, Subitems D, G,  
and H

William D. Stiehm, M.D.

Subitems A, B, C, F and I

Sheldon B. Taubman, M.D.

In vitro procedures only

Camilo Torres, M.D.

Subitems D, G, and H

- B. Radioactive material listed in Item 6 shall be used by Kenneth Chu, Ph.D., as appropriate to fulfill the responsibilities of the Radiation Safety Officer.
- C. The Radiation Therapy Physicist for this license is Kenneth Chu, Ph.D. Only this person may perform full calibrations of the HDR brachytherapy unit and provide decay-corrected output values.

FOR THE NEW YORK STATE DEPARTMENT OF HEALTH

Date: **JAN 30 2004**  
RD/CAC:ers

By Robert E. Dansereau  
Robert E. Dansereau, Chief  
Radioactive Materials Section  
Bureau of Environmental Radiation Protection

cc: Susan Davis, RN, Executive VP/CEO

**NEW YORK STATE DEPARTMENT OF HEALTH  
RADIOACTIVE MATERIALS LICENSE**

License Number 559

Amendment Number 58

DH Number 03-521

Vassar Brothers Hospital  
1 Reade Place  
Poughkeepsie, New York 12601

Attention: Kenneth Chu, Ph.D.  
Radiation Safety Officer

Dear Licensee:

In accordance with the request dated September 20, 2003, signed by Kenneth Chu, Ph.D., and Susan Davis, New York State Department of Health Radioactive Materials License No. 559 is amended as follows.

Change Condition Nos. 6 through 8 to Read:

- | 6. Radioactive Materials<br>(element & mass no.)  | 7. Chemical and/or<br>Physical Form  | 8. Maximum quantity<br>licensee may possess<br>at one time |
|---|--|--|
| A. Any radioactive material as described in 10 NYCRR 16.123(b)(1), except alpha or positron emitting isotopes | A. Any radiopharmaceutical as described in 10 NYCRR 16.123(b)(1)   | A. As necessary for uses in Subitem 9A                     |
| B. Any radioactive material as described in 10 NYCRR 16.123(b)(2), except alpha or positron emitting isotopes | B. Any radiopharmaceutical, generator, or reagent kit as described in 10 NYCRR 16.123(b)(2)                  | B. As necessary for uses in Subitem 9B                     |
| C. Any radioactive material as described in 10 NYCRR 16.123(b)(3), except alpha or positron emitting isotopes | C. Any radiopharmaceutical as described in 10 NYCRR 16.123(b)(3). Iodine 131 restricted to capsule form only | C. As necessary for uses in Subitem 9C                     |

**NEW YORK STATE DEPARTMENT OF HEALTH  
RADIOACTIVE MATERIALS LICENSE**

**CONDITIONS**

License No. 559

Amendment No. 58

6.	Radioactive Materials (element & mass no.)	7.	Chemical and/or Physical Form	8.	Maximum quantity licensee may possess at one time
D.	Any radioactive material listed in 10 NYCRR 16.123(b)(4)	D.	Any radioactive source listed in 10 NYCRR 16.123(b)(4)	D.	1.5 curies total for all radioactive material authorized in Subitem 6D
E.	Iodine 131	E.	Sodium iodide (capsule form only)	E.	As needed
F.	Xenon 133	F.	Gas	F.	500 millicuries
G.	Iridium 192	G.	Sealed source, Nucletron Model 096-001 BYK Mallinckrodt Model CI-L-BV or AEA Technology, Inc., Model CSNOO10-192	G.	Two sources, not to exceed 10 curies per installed source, and 12 curies per source in its shipping container
H.	Strontium 90	H.	Sealed source (Victoreen Model 67-850)	H.	90 millicuries
I.	Fluorine 18	I.	Fluorodeoxyglucose (FDG)	I.	As necessary for uses in Subitem 9I

Change Condition No. 9 to Read:

9. Authorized use (unless otherwise described, the authorized place of use is the licensee's address stated in Item 2, above).
- A. and I. Any diagnostic procedure involving measurement of uptake, dilution, or excretion, as described in 10 NYCRR 16.123 (b) (1).

**NEW YORK STATE DEPARTMENT OF HEALTH  
RADIOACTIVE MATERIALS LICENSE**

---

**CONDITIONS**

License No. 559

Amendment No. 58

## 9. (Continued)

- B. and I. Any diagnostic procedure involving imaging and localization studies, as described in 10 NYCRR 16.123 (b) (2).
- C. Any therapeutic procedure described in 10 NYCRR 16.123 (b) (3).
- D. Any therapeutic procedure described in 10 NYCRR 16.123 (b) (4).
- E. For treatment of hyperthyroidism and thyroid carcinoma.
- F. Evaluation of pulmonary function, blood pool, and/or cerebral blood flow studies.
- G. For use in a Nucletron high dose-rate remote afterloader for treatment of humans; one source installed in the device, and one source in its shipping container as necessary for the replacement of the source in the device.
- H. For treatment of superficial eye conditions.

FOR THE NEW YORK STATE DEPARTMENT OF HEALTH

Date: **OCT 30 2007**  
RD:crsBy: Robert E. Dansereau  
Robert E. Dansereau, Chief  
Radioactive Materials Section  
Bureau of Environmental Radiation Protection

cc: Susan Davis, Executive Vice President/CEO

This is to acknowledge the receipt of your letter/application dated

6/5/2006, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment 37-11507-01  
☒ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 138980.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.